recent
approach
use
nanoparticl
engin
immun
regul
yield
promis
result
preclin
model
diseas
number
nanoparticl
therapi
grow
fuel
innov
nanotechnolog
advanc
understand
underli
pathogenesi
immunemedi
diseas
particular
recent
mechanist
insight
way
nanoparticl
interact
mononuclear
phagocyt
system
impact
function
homeostasi
inflamm
highlight
potenti
nanoparticlebas
therapi
control
sever
inflamm
concurr
restor
peripher
immun
toler
autoimmun
diseas
review
recent
advanc
nanoparticlebas
approach
aim
immunemodul
discuss
context
concept
polymer
nanoparticl
develop
includ
particl
modif
deliveri
factor
associ
success
clinic
deploy
nanotechnolog
revolution
mani
aspect
modern
medicin
includ
diagnost
therapeut
first
nanoparticl
np
therapi
approv
fda
subsequ
numer
np
therapi
approv
focus
optim
safeti
pharmacokinet
properti
smallmolecul
agent
hormon
recent
increas
knowledg
cellular
subset
regulatori
role
variou
member
immun
system
combin
emerg
safe
biocompat
nanoparticl
platform
catalyz
develop
complex
highli
adapt
programm
np
therapi
predict
revolution
standard
care
numer
disord
exampl
np
may
engin
specif
target
cell
mononuclear
phagocyt
system
mp
purpos
restor
peripher
immun
toler
regul
aberr
monocyt
activ
sever
inflamm
fivehundrednanomet
np
neg
zeta
potenti
har
target
circul
monocyt
reduc
potenti
caus
immun
patholog
numer
experiment
diseas
model
includ
west
nile
viru
wnv
enceph
myocardi
infarct
inflammatori
bowel
diseas
ibd
combin
np
specif
autoantigen
also
use
restor
peripher
immun
toler
autoimmun
model
includ
experiment
autoimmun
enceph
eae
addit
np
mayb
util
mop
extran
circul
inflammatori
mediat
function
outcom
np
immun
modul
depend
numer
factor
intrins
np
composit
size
charg
well
extrins
factor
rout
administr
concept
relat
manipul
immun
respons
primari
focu
review
immunolog
consider
therapeut
particl
design
util
np
design
np
particl
size
nm
made
almost
compound
includ
poli
amino
acid
polysaccharid
poli
alphahydroxi
acid
well
nondegrad
compound
gold
silver
carbon
iron
silica
abil
synthes
np
biocompat
biodegrad
polym
polylactidecoglycolid
plga
revolution
use
np
field
immun
modulatori
therapeut
focu
np
engin
deliv
alon
combin
smallmolecul
drug
includ
immun
suppress
chemotherapeut
agent
protein
hormon
antibodi
peptid
vaccin
immun
toler
purpos
dna
part
gene
therapi
approach
mirna
even
machineri
target
cluster
regularli
interspac
short
palindrom
repeat
crispr
compon
geneedit
purpos
clear
physiochem
characterist
unadorn
np
also
alter
immun
respons
independ
associ
activ
pharmaceut
ingredi
primari
function
np
involv
deliveri
specif
cargo
numer
method
develop
due
challeng
associ
effici
encapsul
properti
cargo
straightforward
approach
chemic
conjug
desir
activ
molecul
particl
peptid
antigen
chemic
conjug
np
use
carbodiimid
edc
ecdi
attach
amin
target
carboxyl
acid
particl
variou
chemistri
click
chemistri
michaeltyp
addit
avail
use
base
chemic
group
within
polym
cargo
molecul
altern
activ
molecul
incorpor
particl
directli
use
plga
exemplifi
approach
cargo
either
solubl
organ
solvent
stabl
crystallin
form
dispers
organ
solvent
encapsul
accomplish
use
wateroil
singleemuls
method
deliveri
watersolubl
molecul
incorpor
polymer
np
use
wateroilwat
doubleemuls
method
doubleemuls
method
aqueou
drug
initi
dispers
within
dissolv
polym
solut
second
emuls
form
aqueou
solut
contain
emulsifi
agent
downstream
immunolog
outcom
np
therapi
strongli
influenc
mechan
cellular
uptak
np
enter
cell
via
pathway
allow
access
cytosol
differ
immunemodul
capabl
taken
via
phagocytosi
size
shape
influenc
biodistribut
mechan
particl
uptak
studi
use
broad
rang
standard
cell
line
hela
cho
np
deriv
gold
polystyren
polym
silicon
titanium
iron
oxid
show
ideal
size
shape
particl
uptak
depend
cell
type
nonphagocyt
cell
type
np
nm
diamet
effici
taken
via
caveolaor
clathrinmedi
process
profession
antigenpres
cell
apc
macrophag
dendrit
cell
dc
uptak
impact
shape
size
spheric
np
favor
uptak
kinet
rodshap
np
irrespect
np
size
target
np
phagocyt
critic
aspect
therapi
attempt
manipul
immun
respons
discuss
size
also
affect
np
toxic
nanoparticl
nm
diamet
tend
interact
cellular
organel
includ
mitochondria
nucleu
interact
trigger
cellular
respiratori
gene
toxic
cell
risk
reduc
increas
np
size
presum
larger
np
tend
initi
phagocytosi
effect
isol
particl
sensit
cytoplasm
environ
charg
np
charg
dynam
physicochem
characterist
particl
microenviron
includ
protein
corona
capabl
alter
surfac
charg
np
gener
speak
np
charg
modifi
increas
number
carboxyl
neg
charg
amin
posit
charg
group
surfac
np
studi
use
differ
np
charg
clearli
shown
factor
influenc
uptak
mechan
downstream
immun
outcom
instanc
rel
anion
particl
cation
np
appear
taken
readili
via
clathrinmedi
process
furthermor
posit
charg
antigenload
np
significantli
effect
stimul
respons
either
intraderm
mucos
pulmonari
inocul
wherea
anion
particl
stimul
b
cell
respons
poorli
similar
condit
abil
cation
particl
stimul
respons
associ
preferenti
dc
uptak
particl
propens
cation
particl
regul
posit
costimulatori
molecul
howev
cation
np
may
also
alter
mitochondri
endoplasm
reticulum
function
trigger
product
reactiv
oxygen
speci
proinflammatori
cytokin
well
cell
death
event
may
underli
adjuv
effect
cation
np
attempt
har
phenomenon
clinic
need
address
consequ
offtarget
toxic
anion
np
contrast
associ
littl
toxic
furthermor
np
charg
mv
found
antiinflammatori
properti
combin
antigen
induc
antigenspecif
immun
toler
phenomenon
associ
abil
specif
target
scaveng
receptor
marco
monocyt
macrophag
stiff
also
affect
biolog
impact
np
np
made
rigid
materi
may
associ
increas
potenti
embol
flexibl
polymerbas
np
easili
deform
may
gain
better
access
tissu
complex
vascular
chang
associ
inflamm
fluiditi
np
affect
abil
antigenload
np
stimul
immun
respons
thu
intramuscular
solidphas
antigencontain
liposom
immun
elicit
robust
respons
similarli
administ
fluidphas
liposom
stimulatori
abil
solidphas
particl
propos
result
format
immobil
antigen
particl
depot
similar
observ
tradit
oilinwat
emuls
aluminum
adjuv
result
prolong
suppli
antigen
apc
also
associ
upregul
posit
costimulatori
molecul
support
effici
cell
prime
contrast
intramuscularli
inject
fluidstat
liposom
rapidli
remov
appear
stimul
posit
costimul
much
less
capabl
stimul
cell
respons
whether
intramuscular
fluid
liposomeantigen
combin
induc
peripher
immun
toler
test
intraperiton
ip
administr
fluid
ovadecor
liposom
induc
antigenspecif
ige
nonrespons
argu
occur
cellindepend
fashion
increas
level
igg
ip
administr
suggest
immun
deviat
notwithstand
find
highlight
import
understand
contribut
fluiditi
stiff
npmediat
manipul
immun
outcom
trend
immunolog
juli
vol
factor
associ
particl
opson
base
vitro
studi
fetal
bovin
serum
protein
corona
form
around
np
twostep
process
first
step
highaffin
protein
rapidli
bind
np
form
primari
corona
second
step
protein
lower
affin
bind
either
directli
np
protein
primari
corona
form
secondari
corona
constitu
protein
corona
thu
inevit
impact
protein
content
serum
thu
homeostat
immun
respons
regul
studi
show
protein
high
abund
albumin
compris
signific
proport
primari
corona
howev
found
np
differ
charg
bind
signific
amount
lessabund
protein
plasma
wnvinfect
anim
vivo
format
protein
corona
associ
littl
impact
np
deliveri
function
howev
protein
bind
np
could
feasibl
alter
np
charg
mask
function
group
import
np
target
certain
receptor
andor
enhanc
clearanc
np
phagocyt
therefor
np
engin
effort
focus
develop
techniqu
reduc
phenomenon
mani
method
inform
experi
gain
increas
halflif
biolog
therapi
commonli
use
process
includ
coat
np
surfac
polymer
ethylen
glycol
peg
low
molecular
weight
deriv
polyethylen
oxid
peo
peg
increas
surfac
hydrophil
result
improv
circul
np
halflif
due
reduc
serum
protein
bind
unlik
peg
use
peo
develop
stealth
np
associ
potenti
toxic
issu
like
peg
peo
form
mushroomor
brushlik
configur
surfac
np
unlik
peg
howev
peo
may
activ
complement
pathway
mushroomlik
configur
wherea
brushlik
configur
trigger
lectinspecif
complement
cascad
interestingli
although
np
coat
may
prolong
np
serum
halflif
cell
mp
still
appear
involv
primari
clearanc
mechan
intraven
infus
np
although
observ
highlight
possibl
modul
np
surfac
reduc
opson
event
also
serv
potent
warn
chang
dramat
alter
biocompat
np
biodistribut
np
examin
mani
studi
wide
vari
condit
result
divers
dataset
often
make
specif
conclus
difficult
figur
exampl
studi
often
fail
perfus
anim
tissu
examin
make
difficult
discrimin
np
bloodstream
np
adher
endothelium
np
gain
access
organ
parenchyma
nonperfus
anim
intraven
iv
np
administr
high
intraven
np
content
organ
larg
blood
volum
make
assess
biodistribut
extrem
difficult
modal
accur
evalu
np
interact
specif
cell
tissu
virtual
imposs
dr
gett
njc
king
unpublish
np
introduc
bodi
gener
perceiv
foreign
innat
immun
mechan
protect
invas
pathogen
usual
recogn
remov
potenti
degrad
np
rapidli
subcutan
administ
np
expos
highli
special
immun
environ
contain
numer
migratori
antigenpres
subset
well
rel
sedentari
structur
cell
fibroblast
context
local
lymphat
drainag
system
similar
mucos
intramuscular
site
lymphat
carri
apc
local
lymph
node
process
contain
antigen
materi
occur
small
particl
nm
may
drain
freeli
subcutan
muscular
even
mucos
site
applic
local
lymph
node
howev
particl
nm
size
must
phagocytos
local
bloodderiv
phagocyt
transport
drain
lymph
node
freeli
drain
apcassoci
np
arriv
subcapsular
sinu
lymph
node
region
rich
macrophag
spleen
import
coordin
dendrit
cell
stimul
effect
cell
respons
invad
pathogen
subcutan
deliveri
np
effect
stimul
immun
respons
numer
b
cell
antigen
np
rare
escap
lymph
node
gener
contain
foreign
antigen
materi
limit
spread
invas
pathogen
ultrafin
np
nm
size
seem
circumv
sequestr
howev
size
np
associ
increas
potenti
oncogenesi
toxic
intraven
administ
np
theoret
access
entir
bodi
howev
biodistribut
strongli
influenc
size
exampl
intraven
infus
nanoparticl
diamet
nm
pass
glomeruli
detect
urin
except
vascular
integr
disrupt
intraven
deliv
np
nm
diamet
cross
endotheli
barrier
bloodbrain
barrier
endotheli
line
heart
reproduct
organ
gastrointestin
tract
particl
irrespect
surfac
modif
predomin
engulf
trend
immunolog
juli
vol
circul
monocyt
cell
mp
line
fenestr
endothelium
spleen
liver
latter
cell
essenti
daili
filter
phagocytosi
apoptot
cell
debri
blood
cell
critic
associ
mainten
peripher
toler
deliveri
np
via
iv
rout
absenc
adjuv
promot
immun
toler
provid
avenu
modul
circul
inflammatori
monocyt
clear
rout
administr
np
impact
organ
distribut
possibl
downstream
immun
outcom
point
acknowledg
fda
immunogen
assess
guidanc
therapeut
protein
therapi
document
author
note
rel
administr
rout
iv
administr
protein
proteincontain
therapi
associ
reduc
risk
immun
stimul
cytokinereleas
syndromelik
event
potenti
np
optim
vaccin
examin
extens
deliveri
immunesuppress
agent
np
horizon
recent
expand
includ
use
np
control
immun
patholog
associ
sever
inflammatori
respons
well
restor
peripher
immun
toler
novel
avenu
discuss
greater
detail
innat
immun
respons
essenti
host
surviv
howev
abnorm
overact
acut
inflammatori
respons
result
immun
patholog
result
cytokinereleas
syndrom
caus
biolog
therapi
aberr
innat
immun
cell
function
associ
numer
infecti
agent
includ
ebola
influenza
flavivirus
mer
well
associ
syndrom
acut
enceph
syndrom
sever
acut
respiratori
syndrom
sar
overproduct
cytokin
inflammatori
mediat
common
occurr
poorli
regul
immun
respons
phenomenon
sever
lifethreaten
left
uncheck
treatment
option
limit
largedos
steroid
frequent
prescrib
treatment
recent
extracorpor
filter
cytosorb
use
dialysi
effect
sepsi
howev
treatment
modal
limit
need
expens
dialysi
machineri
np
may
revolution
approach
np
may
engin
vivo
use
surfac
modif
attach
antibodi
moieti
bind
specif
toxin
andor
protein
safe
digest
liver
spleen
phagocyt
recent
rodent
proofofconcept
studi
infus
highli
neg
charg
immunemodifi
np
imp
absorb
certain
blood
protein
includ
famili
heat
shock
protein
final
remov
destroy
cell
mononuclear
phagocyt
system
furthermor
mechan
may
also
use
captur
concentr
certain
circul
protein
imp
shown
bind
annexin
accumul
annexin
present
particular
leukocyt
subset
broad
immun
outcom
exampl
annexin
np
may
reduc
neutrophil
via
induct
apoptosi
andor
promot
cell
activ
human
monocyt
express
lo
hi
well
receptor
integrin
major
monocyt
popul
normal
blood
human
hi
defin
classic
inflammatori
monocyt
mice
popul
identifi
hi
lo
lo
phenotyp
contrast
much
smaller
lo
hi
nonclass
patrol
monocyt
subset
compris
blood
monocyt
human
defin
lo
hi
lo
hi
mice
hi
hi
hi
hi
subset
defin
intermedi
group
human
mice
respect
compar
rna
profil
suggest
human
intermedi
monocyt
function
closest
mous
classic
monocyt
work
mani
area
includ
infecti
diseas
hypoxia
autoimmun
cancer
show
defin
wave
inflammatori
monocyt
recruit
inflam
tissu
express
chemokin
target
tissu
cell
may
differenti
differ
effector
cell
includ
dc
macrophag
even
cell
microgli
phenotyp
depend
prevail
solubl
factor
milieu
case
cell
import
housekeep
function
ie
digest
clear
tissu
debri
tissu
remodel
howev
mani
case
express
high
level
via
induc
express
well
increas
level
nadph
oxidas
cathepsin
myeloperoxidas
may
demonstr
contribut
tissu
damag
numer
condit
includ
experiment
autoimmun
encephalomyel
myocardi
infarct
viral
enceph
monocyt
manag
recent
emerg
uniqu
potenti
treatment
modal
limit
damag
associ
acut
phase
inflamm
numer
diseas
indic
circul
serv
primari
conduit
monocyt
travel
bone
marrowspleen
throughout
bodi
site
inflamm
make
highli
suscept
target
via
intraven
administ
np
one
approach
involv
combin
sirna
liposom
shown
promis
anim
model
howev
recent
shown
np
deriv
broad
array
biodegrad
nondegrad
compound
molecul
without
tradit
activ
pharmaceut
ingredi
api
addit
immunestimul
agent
abl
target
precis
scaveng
receptor
reduc
circul
inflammatori
monocyt
specif
imp
ie
np
highli
neg
surfac
charg
bind
high
specif
inflammatori
monocyt
mark
sequestr
spleen
therebi
prevent
migrat
site
inflamm
subsequ
differenti
particip
pathogen
immun
respons
sequest
monocyt
either
undergo
apoptosi
differenti
dc
role
dc
remain
complet
defin
imp
treatment
associ
expans
shortliv
regulatori
cell
treg
popul
dr
gett
et
al
unpublish
emerg
subsequ
disappear
treg
correl
treatment
efficaci
eae
model
monocyt
manag
approach
effect
numer
model
inflamm
tabl
phase
clinic
studi
plan
autoimmun
result
breakdown
peripher
toler
activ
immunolog
process
usual
control
selfreact
b
cell
holi
grail
autoimmun
therapi
restor
induct
robust
peripher
immun
toler
cell
caus
diseas
use
apoptot
cell
induc
toler
uncov
origin
shown
promis
earli
clinic
studi
howev
use
cell
numer
manufactur
cost
patient
access
issu
serendipit
discoveri
neg
charg
np
target
specif
scaveng
receptor
local
region
spleen
similar
apoptot
cell
catalyz
develop
synthet
cell
replac
could
carri
antigen
immun
toler
induct
subsequ
sever
npbase
approach
induct
immun
toler
function
via
altern
mechan
emerg
focu
har
natur
capabl
np
deliv
antigen
tolerogen
fashion
approach
deliv
antigen
combin
smallmolecul
immun
suppress
target
aryl
hydrocarbon
receptor
chang
dc
phenotyp
brief
discuss
mechan
np
shown
induc
toler
focu
har
np
deliveri
antigen
without
addit
immun
suppress
modul
agent
induct
immun
toler
use
np
least
rodent
model
depend
sever
factor
first
foremost
np
load
correct
antigen
target
apc
capabl
regul
cell
function
concurr
support
induct
andor
expans
treg
abil
antigenload
np
inactiv
exquisit
specif
autoreact
cell
clone
depend
deliveri
antigen
process
apc
directli
recogn
autoreact
cell
primari
hurdl
antigenspecif
toler
approach
remain
identif
diseaseassoci
antigen
epitop
thu
mani
autoimmun
diseas
epitop
associ
diseas
remain
defin
identif
complic
multipl
sclerosi
ms
exampl
fact
appropri
target
antigen
may
chang
time
due
epitop
spread
nevertheless
disord
includ
celiac
diseas
ms
type
diabet
numer
antigen
identifi
anoth
potenti
strategi
har
natur
mechan
may
initi
autoimmun
obviat
need
know
precis
epitop
may
use
fulllength
protein
encapsul
fulllength
protein
may
allow
host
apc
liber
numer
nondefin
epitop
autoantigen
similar
process
presum
underli
initi
diseas
appropri
target
subsequ
tolerogen
stimul
certain
popul
apc
crucial
immun
toler
induct
incorrect
target
result
immun
stimul
exampl
antigenload
np
design
target
induc
robust
product
type
interferon
well
cell
prolifer
wherea
particl
target
marco
macrophag
liver
spleen
induc
toler
highlight
fact
apc
popul
creat
equal
popul
better
equip
toler
induct
other
equip
immun
induct
german
splenic
liver
macrophag
popul
express
numer
scaveng
receptor
homeostasi
play
import
role
recognit
recycl
die
leukocyt
red
blood
cell
debri
daili
basi
importantli
activ
occur
without
trigger
inflamm
break
peripher
immun
toler
tolerogen
imp
timp
design
take
advantag
marcotarget
abil
highli
neg
charg
np
intraven
administr
antigenencapsul
imp
result
biodistribut
similar
apoptot
debri
particl
home
marco
macrophag
liver
spleen
figur
importantli
one
cours
timp
result
toler
induct
cell
anergi
parallel
induct
treg
mechan
subsequ
shown
applic
induct
longliv
toler
numer
even
rodent
diseas
model
tabl
inher
immunolog
behavior
lymph
node
especi
phenomenon
histor
known
lymph
node
shutdown
make
difficult
target
liver
spleen
popul
use
nonintraven
rout
administr
context
timp
ip
administr
result
partial
toler
subcutan
oral
deliveri
fail
induc
regul
case
subcutan
administr
even
result
sensit
andor
diseas
exacerb
lymph
node
appear
devoid
inher
tolerogen
macrophag
popul
may
unsurpris
sinc
epitheli
surfac
consist
challeng
opportunist
pathogen
potenti
defens
mechan
epitheli
lymph
node
apc
popul
tend
express
higher
level
costimulatori
molecul
apc
elsewher
dr
gett
et
al
unpublish
attempt
util
np
combin
antigen
immunesuppress
agent
rapamycin
alter
dc
phenotyp
vivo
potenti
induc
toler
rapamycin
known
two
decad
tolerogen
effect
combin
antigen
adopt
transfer
rapamycintr
dc
promot
longterm
surviv
skin
graft
rodent
transplant
recipi
context
np
haddadi
colleagu
show
rapamycinload
plga
np
preferenti
bound
dc
induc
immatur
tolerogen
phenotyp
recent
maldonado
colleagu
show
biweekli
subcutan
inject
pegyl
plga
rapamycin
figur
propos
mechan
action
toler
induct
use
toleragen
immun
modifi
nanoparticl
timp
induct
toler
use
timp
requir
antigenload
particl
must
deliv
intraven
particl
taken
via
scaveng
receptormedi
process
marco
shown
involv
particl
uptak
toler
induct
marco
express
circul
inflammatori
monocyt
well
margin
zone
macrophag
base
timp
size
nm
phagocytosi
like
primari
uptak
mechan
uptak
macrophag
popul
produc
tgf
factor
numer
immun
regulatori
function
includ
modul
level
antigenpres
cell
apc
integr
apc
respons
coordin
regul
autoreact
cell
via
three
predomin
pathway
context
activ
autoreact
cell
upregul
neg
costimulatori
molecul
apc
includ
promot
autoreact
cell
anergi
apoptosi
cell
regul
result
tcr
stimul
signal
without
regulatori
cell
induct
although
precis
tempor
contribut
regulatori
mechan
requir
examin
evid
suggest
toler
result
earli
anergi
regulatori
cell
reg
play
major
role
longterm
toler
mainten
trend
immunolog
juli
vol
ova
np
significantli
reduc
product
ovaspecif
igg
howev
note
repeat
ova
exposur
titer
observ
increas
time
treat
mice
use
similar
particl
although
load
plp
author
also
show
subcutan
inject
could
reduc
incid
eae
howev
unlik
intraven
infus
protect
anoth
strategi
focus
alter
dc
phenotyp
administr
np
agon
ligandactiv
transcript
factor
aryl
hydrocarbon
receptor
activ
aryl
hydrocarbon
receptor
dc
support
differenti
tolerogen
apc
support
expans
treg
use
mog
plp
eae
model
pegyl
gold
np
load
aryl
hydrocarbon
receptor
agonist
carbonyl
acid
methyl
ester
mog
plp
test
abil
amelior
diseas
test
subcutan
weekli
ip
iv
administr
np
success
result
diseas
manag
altern
approach
deliv
npantigen
cocktail
apc
involv
direct
target
specif
cell
popul
associ
diseas
exampl
shown
polyclon
treg
expand
use
np
coat
leukemia
inhibitori
factor
antigenspecif
approach
includ
use
polymer
monomer
peptid
mhc
pmhc
may
select
delet
cell
express
cognat
cell
receptor
recogn
pmhc
complex
shown
efficaci
experiment
model
transplant
type
diabet
howev
clinic
translat
complic
requir
exquisit
knowledg
autoreact
epitop
nevertheless
field
rapidili
progress
toward
clinic
translat
np
use
treatment
variou
diseas
state
use
inher
properti
np
direct
antigen
uptak
particular
apc
subset
induct
immun
toler
use
np
immuneregul
agent
recent
emerg
mani
unansw
question
remain
futur
develop
novel
biocompat
polym
well
increas
understand
precis
interplay
physiochem
characterist
np
associ
downstream
immun
interact
like
result
expans
field
next
year
sever
clinic
studi
expect
begin
test
abil
highli
neg
charg
plga
np
reduc
sever
inflamm
myocardi
infarct
acut
enceph
syndrom
furthermor
evid
suggest
clinic
test
np
toler
platform
area
pemphigu
vulgari
type
diabet
ms
even
celiac
diseas
like
occur
next
year
http
www
courpharmacom
http
selectabiocom
move
forward
question
surround
appropri
np
formul
safeti
need
address
barrier
antigen
identif
context
autoimmun
treatment
also
remain
least
studi
inform
futur
np
approach
success
howev
therapi
revolution
treatment
mani
diseas
place
npbase
therapi
forefront
immunemodul
therapeut
review
trend
immunolog
juli
vol
